StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –

Vaxart free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vaxart's free cash flow for the twelve months ending Jun 30, 2026 was $33.38M. For fiscal 2025 it was $7.57M. The highest annual figure on record is $7.57M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.57M–
FY2024Dec 31, 2024-$45.32M–
FY2023Dec 31, 2023-$72.32M–
FY2022Dec 31, 2022-$104.38M–
FY2021Dec 31, 2021-$64.99M–
FY2020Dec 31, 2020-$24.97M–
FY2019Dec 31, 2019-$13.94M–
FY2018Dec 31, 2018-$15.26M–
FY2016Jun 30, 2016-$14.30M–
FY2015Jun 30, 2015-$9.70M–
FY2014Jun 30, 2014-$3.40M–
FY2013Jun 30, 2013-$14.90M–
FY2012Jun 30, 2012-$17.20M-376.8%
FY2009Dec 26, 2009$6.21M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$2.74M–
Q1 FY2026CQ1 2026Mar 31, 2026-$2.50M–
Q4 FY2025CQ4 2025Dec 31, 2025$30.66M–
Q3 FY2025CQ3 2025Sep 30, 2025$2.48M–
Q2 FY2025CQ2 2025Jun 30, 2025-$15.84M–
Q1 FY2025CQ1 2025Mar 31, 2025-$9.73M–
Q4 FY2024CQ4 2024Dec 31, 2024-$7.39M–
Q3 FY2024CQ3 2024Sep 30, 2024-$4.21M–
Q2 FY2024CQ2 2024Jun 30, 2024-$12.40M–
Q1 FY2024CQ1 2024Mar 31, 2024-$21.32M–
Q4 FY2023CQ4 2023Dec 31, 2023-$13.42M–
Q3 FY2023CQ3 2023Sep 30, 2023-$15.28M–
Q2 FY2023CQ2 2023Jun 30, 2023-$17.93M–
Q1 FY2023CQ1 2023Mar 31, 2023-$25.70M–
Q4 FY2022CQ4 2022Dec 31, 2022-$33.05M–
Q3 FY2022CQ3 2022Sep 30, 2022-$16.64M–
Q2 FY2022CQ2 2022Jun 30, 2022-$28.23M–
Q1 FY2022CQ1 2022Mar 31, 2022-$26.46M–
Q4 FY2021CQ4 2021Dec 31, 2021-$16.83M–
Q3 FY2021CQ3 2021Sep 30, 2021-$15.59M–
Q2 FY2021CQ2 2021Jun 30, 2021-$15.36M–
Q1 FY2021CQ1 2021Mar 31, 2021-$17.21M–
Q4 FY2020CQ4 2020Dec 31, 2020-$11.67M–
Q3 FY2020CQ3 2020Sep 30, 2020-$9.56M–
Q2 FY2020CQ2 2020Jun 30, 2020-$530.00K–
Q1 FY2020CQ1 2020Mar 31, 2020-$3.21M–
Q4 FY2019CQ4 2019Dec 31, 2019-$3.80M–
Q3 FY2019CQ3 2019Sep 30, 2019-$4.46M–
Q2 FY2019CQ2 2019Jun 30, 2019-$476.00K-106.9%
Q1 FY2019CQ1 2019Mar 31, 2019-$5.21M–
Q4 FY2018CQ4 2018Dec 31, 2018-$5.90M-689.7%
Q3 FY2018CQ3 2018Sep 30, 2018-$5.53M-2865.5%
Q2 FY2018CQ2 2018Jun 30, 2018$6.90M–
Q1 FY2018CQ1 2018Mar 31, 2018-$10.73M–
Q4 FY2016CQ2 2016Jun 30, 2016$1.00M–
Q4 FY2015CQ2 2015Jun 30, 2015$200.00K–

More Vaxart figures

See a number that looks wrong?